Highlights: The Coronavirus disease 2019 (COVID-19) is having devastating effects on the health and socio-economic conditions worldwide. It is caused by beta-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Favipiravir, an oral broad-spectrum antiviral agent, has been approved for treating mild to moderate COVID-19 infections in many countries, including India. 1 This infographic summarizes the pharmacology of favipiravir and its role in the management of COVID-19.